Form 8-K - Current report:
SEC Accession No. 0001213900-25-020366
Filing Date
2025-03-05
Accepted
2025-03-05 08:07:29
Documents
14
Period of Report
2025-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0232641-8k_protara.htm   iXBRL 8-K 26010
2 PRESS RELEASE DATED MARCH 5, 2025, ISSUED BY THE REGISTRANT ea023264101ex99-1_protara.htm EX-99.1 73871
  Complete submission text file 0001213900-25-020366.txt   286206

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20250305.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tara-20250305_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20250305_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0232641-8k_protara_htm.xml XML 3693
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 25708911
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)